Open AccessCaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
Author(s) -
Laurence Albigès,
Manuela Schmidinger,
Naila Taguieva-Pioger,
David Pérol,
Viktor Grünwald,
Eric Guémas
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1006
Subject(s) - cabozantinib , medicine , nivolumab , ipilimumab , oncology , renal cell carcinoma , clinical endpoint , axitinib , tyrosine kinase inhibitor , cohort , cancer , clinical trial , immunotherapy , sunitinib
Cabozantinib is an inhibitor of multiple tyrosine kinases, including AXL, MET and VEGF receptors. Here, we describe the rationale and design for the phase II CaboPoint trial (ClinicalTrials.gov identifier: NCT03945773), which will evaluate the efficacy and safety of cabozantinib as a second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma whose disease has progressed despite checkpoint inhibitor therapy. Patients will be recruited into two cohorts: prior ipilimumab plus nivolumab (cohort A) or prior checkpoint inhibitor–VEGF-targeted therapy (cohort B). All patients will receive once-daily oral cabozantinib 60 mg for up to 18 months. The primary end point is objective response rate. Secondary end points include overall survival, progression-free survival and safety.